Biotech Values

[jq1234]

Their lead program isn't bi-specific or multi-specific antibody. Their mAb against ErbB3 is probably the most advanced antibody for this particular target. So, it is more the platform for bi-specific/multi-specific I am interested in at the moment. I was interested in MITI's bi-specific many years ago when very few were, MEDX's immunotherapy when very few were. So MACK is the one similar to those two I am out there at the moment. MACK is well below IPO price now.